In The News
ConstructionPRO Test 1
ConstructionPRO Test 2
ConstructionPRO Test 3
ConstructionPRO Test 4
ConstructionPRO Test 5
ConstructionPRO Test 6
ConstructionPRO Test 7
High Court rejects Qantas appeal in ground crew sacking case
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Lawyer’s defamation case fails serious harm test, judge finds
Biosimilar drug makers settle IP spat over arthritis drug Humira
Clayton Utz 2020-01-21 2:21 pmBy Christine Caulfield | Melbourne
Please login to bookmark Close

German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au